ReviewTherapeutic advances in neurological disorders2026
Economic value of anti-CD20 therapies in multiple sclerosis: a systematic review of cost-effectiveness studies.
Johannes Heinemann et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.